

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS**

1. (previously presented) A method of treating a human body having cancer comprising administering an effective therapeutic amount of ET-743 in combination with an effective therapeutic amount of a 5-fluorouracil pro-drug.
2. (canceled)
3. (previously presented) The method according to claim 1, wherein ET-743 is administered in combination with capecitabine.
4. (original) The method according to claim 3, wherein capecitabine and ET-743 are provided as separate medicaments for administration at different times.
5. (original) The method according to claim 4, wherein capecitabine is administered in a dose range between 1500 to 2500 mg/m<sup>2</sup>/day.
6. (original) The method according to claim 4, wherein ET-743 is administered in a dose range between 0.75 and 1.4 mg/m<sup>2</sup>.

7. (original) The method according to claim 5 or 6, wherein capecitabine is administered in a dosage of up to  $2000 \text{ mg/m}^2/\text{day}$  and ET-743 is administered in a dosage of up to  $1.2 \text{ mg/m}^2$ .
8. (original) The method according to claim 7, wherein capecitabine is administered in a dosage about  $1600 \text{ mg/m}^2/\text{day}$  and ET-743 is administered in a dosage about  $0.9 \text{ mg/m}^2$ .
9. (original) The method according to claim 5 or 6, wherein capecitabine is orally administered.
10. (original) The method according to claim 9, wherein ET-743 is administered by intravenous injection.
11. (original) The method according to claim 10, wherein the infusion time for intravenous injection of ET-743 is up to 24 hours.
12. (original) The method according to claim 11, wherein the infusion time for intravenous injection of ET-743 is about 3 hours for ET-743.
13. (original) The method according to claim 10, where the infusions of ET-743 are carried out at an interval of 1 to 6 weeks.
14. (original) The method according to claim 13, wherein the infusion of ET-743 is carried out once every 21 days.

15. (original) The method according to claim 14, wherein the infusion of ET-743 is carried out on day 1 and the administration of capecitabine from days 2 to 15, every 21 days.

16. (original) The method according to claim 15, wherein capecitabine is administered twice-daily.

17. (previously presented) A method according to claim 1, in which the patient has a cancer selected from sarcoma, osteosarcoma, ovarian cancer, breast cancer, melanoma, vaginal cancer, colorectal cancer, gastric cancer, adenocarcinoma, mesothelioma, renal cancer, endometrial cancer, cholangiocarcinoma and lung cancer.

18. (previously presented) A method according to claim 17, in which the patient has a cancer selected from sarcoma, breast cancer, gastric cancer, vaginal cancer, cholangiocarcinoma and adenocarcinoma.

19-20. (canceled)

21. (original) A medical kit for administering ET-743 in combination with capecitabine, comprising a supply of ET-743 in dosage units for at least one cycle, wherein each dosage unit contains the appropriate amount of ET-743 for the treatments and a pharmaceutically acceptable carrier, and printed instructions for administering ET-743 according to a dosing schedule.

22. (previously presented) The method according to claim 5, wherein capecitabine is administered in a dosage of about 2000 mg/m<sup>2</sup>/day.

23. (previously presented) The method according to claim 5, wherein capecitabine is administered in a dosage of about 1600 mg/m<sup>2</sup>/day.

24. (previously presented) The method according to claim 6, wherein ET-743 is administered in a dose range between 0.9 and 1.2 mg/m<sup>2</sup>.

25. (previously presented) The method according to claim 6, wherein ET-743 is administered in a dosage of about 0.9 mg/m<sup>2</sup>.

26. (previously presented) The method according to claim 6, wherein ET-743 is administered in a dosage of about 0.9 mg/m<sup>2</sup> on day 1 of a 3 week cycle.

27. (previously presented) The method according to claim 3, wherein capecitabine is administered in a dosage of about 1600 mg/m<sup>2</sup>/day and ET-743 is administered in a dosage range between 0.9 and 1.2 mg/m<sup>2</sup>.

28. (previously presented) The method according to claim 27, wherein the infusion of ET-743 is carried out on day 1 and the administration of capecitabine from days 2 to 15, every 21 days.

29. (previously presented) The method according to claim 10, wherein commencement of administration of capecitabine is on a day after ET-743 administration.